Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform

Tempus’ generative AI-enabled clinical assistant is designed to support providers in unlocking new insights and efficiencies

CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration marks a new chapter in the organizations’ shared commitment to harnessing data and AI to advance patient care.

Northwestern Medicine and Tempus clinical, operations, and technical teams are working together to customize the platform to specifically address the health system’s needs. Through the integration of David, Northwestern Medicine will adopt core parts of Tempus’ AI infrastructure to allow its AI applications to be underpinned by a multimodal patient record and to co-develop, deploy, and real-time monitor novel AI algorithms and agents into the David experience.

Building on almost a decade of collaboration at the forefront of data-driven healthcare, Northwestern Medicine and Tempus are now pioneering the next generation of clinical decision support. Deploying David directly into the EHR empowers Northwestern Medicine’s clinical teams with real-time, AI-enabled insights at every point of care, all in an effort to streamline complex treatment decisions, reduce administrative burden, and ultimately improve patient outcomes. With this integration, clinical teams will be able to:

• Build custom AI agents tailored to Northwestern Medicine’s unique workflows, further enhancing efficiency and care quality.
• Query patient data across the EHR using natural language, surfacing relevant information in seconds.
• Automate pre-appointment preparation, with AI-generated patient summaries and treatment histories.
• Receive real-time support during appointments, including intelligent note-taking and key information highlights.
• Streamline post-appointment tasks, such as documentation, treatment planning, prior authorizations, and clinical trial matching.

“Through this expanded collaboration, we will have the ability to thoughtfully deploy AI in a way that will enhance our ability to provide care to our patients,” said Howard Chrisman, MD, president and chief executive officer, Northwestern Memorial HealthCare. “Providing our physicians and clinical care teams with data and relevant information in real-time, tailored to each patient, is the next leap forward in the delivery of care.”

“Northwestern Medicine was our first genomic sequencing partner almost ten years ago, and together we led the field into generating multimodal data at scale. A decade later, we are now embarking on a new chapter that will demonstrate how generative AI can transform the way healthcare is delivered,” said Eric Lekfofsky, Founder and CEO at Tempus. “The integration of David into Northwestern Medicine’s EHR is a major step forward in our mission to connect multiple data modalities and deliver actionable insights in real time.”

About Northwestern Medicine

To learn more about Northwestern Medicine, please visit NM.org.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of David and its capabilities for customers and the collaboration with Northwestern Medicine. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.